JAC Advance Access originally published online on June 11, 2007
Journal of Antimicrobial Chemotherapy 2007 60(2):424-428; doi:10.1093/jac/dkm145
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005
Institute of Medical Microbiology, National Reference Centre for Systemic Mycoses, University Clinics, Göttingen, Germany
Received 26 September 2006; returned 15 January 2007; revised 30 March 2007; accepted 17 April 2007
* Correspondence address. Institute of Medical Microbiology, National Reference Centre for Systemic Mycoses, Kreuzbergring 57, D-37075 Göttingen, Germany. Tel: +49-551-395807; Fax: +49-551-395861; E-mail: mborg{at}gwdg.de
Objectives: Data on fungal infections occurring in Germany are rare to date. The aim of the present study was to survey the epidemiological situation in Germany, to provide data on the susceptibility of the fungal isolates to antifungals.
Methods: Five hundred and sixty-one Candida isolates were collected from primarily sterile sites of patients from July 2004 to August 2005 with the aid of a nationwide established laboratory network, MykolabNet-D. The MICs of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and caspofungin were determined using the microdilution reference procedure M27-A2 of the CLSI.
Results: Candida albicans was the most frequently isolated species (58.5%), followed by Candida glabrata (19.1%), Candida parapsilosis (8.0%) and Candida tropicalis (7.5%). In contrast, the isolation rate of Candida krusei (1.4%) was low. Candida kefyr appeared as a new pathogen in this profile. Amphotericin B revealed excellent activity, with only three resistant isolates (0.5%). A total of 25 isolates (4.5%) showed resistance against flucytosine. All 25 isolates were identified as C. tropicalis indicating a peculiarity within German isolates. The resistance rate of all tested isolates to fluconazole and to itraconazole was 3.7% and 17.6%, respectively. According to the provisional breakpoints, two isolates (0.4%) were tested as resistant to voriconazole. Caspofungin was active against the majority of isolates where an intrinsic resistance is unknown.
Conclusions: This latest German survey of isolates from patients with fungaemia demonstrates a favourable situation with respect to antifungal susceptibilities for the antifungal substances tested.
Keywords: azoles , azole resistance , flucytosine , caspofungin , susceptibility testing
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Mandras, V. Tullio, V. Allizond, D. Scalas, G. Banche, J. Roana, F. Robbiano, G. Fucale, A. Malabaila, A. M. Cuffini, et al. In Vitro Activities of Fluconazole and Voriconazole against Clinical Isolates of Candida spp. Determined by Disk Diffusion Testing in Turin, Italy Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1657 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. J. de Groot, E. A. Kraneveld, Q. Y. Yin, H. L. Dekker, U. Gross, W. Crielaard, C. G. de Koster, O. Bader, F. M. Klis, and M. Weig The Cell Wall of the Human Pathogen Candida glabrata: Differential Incorporation of Novel Adhesin-Like Wall Proteins Eukaryot. Cell, November 1, 2008; 7(11): 1951 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Trofa, A. Gacser, and J. D. Nosanchuk Candida parapsilosis, an Emerging Fungal Pathogen Clin. Microbiol. Rev., October 1, 2008; 21(4): 606 - 625. [Abstract] [Full Text] [PDF]
|
|